SPL Mapping FHIR Implementation Guide
0.1.0 - Build CI United States of America flag

SPL Mapping FHIR Implementation Guide, published by HL7 International / Biomedical Research and Regulation. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/fhir-spl/ and changes regularly. See the Directory of published versions

Example Bundle: EnbrelSyringeLabelBundle


Generated Narrative: Composition

ResourceComposition "EnbrelSyringeLabelComposition"

Profile: ProductSubmissionDocument

VersionNumber: 197

identifier: Uniform Resource Identifier (URI)/urn:uuid:a002b40c-097d-47a5-957f-7a7b1807af7f

status: final

type: HUMAN PRESCRIPTION DRUG LABEL (LOINC#34391-3)

date: 2021-12-13

author: See on this page: Organization/ImmunexCorporation

title: These highlights do not include all the information needed to use ENBREL safely and effectively. See full prescribing information for ENBREL. <br/> <br/>ENBREL<sup>®</sup> (etanercept) injection, for subcutaneous use <br/>ENBREL<sup>®</sup> (etanercept) for injection, for subcutaneous use <br/>Initial U.S. Approval: 1998


WARNING: SERIOUS INFECTIONS and MALIGNANCIES

SPL UNCLASSIFIED SECTION

SPL UNCLASSIFIED SECTION

1 INDICATIONS AND USAGE

1.1 Rheumatoid Arthritis

1.2 Polyarticular Juvenile Idiopathic Arthritis

1.3 Psoriatic Arthritis

1.4 Ankylosing Spondylitis

1.5 Plaque Psoriasis

2 DOSAGE AND ADMINISTRATION

2.1 Adult Patients

SPL UNCLASSIFIED SECTION

SPL UNCLASSIFIED SECTION

2.2 Pediatric Patients

2.3 Preparation of Enbrel

SPL UNCLASSIFIED SECTION

SPL UNCLASSIFIED SECTION

SPL UNCLASSIFIED SECTION

SPL UNCLASSIFIED SECTION

SPL UNCLASSIFIED SECTION

2.4 Monitoring to Assess Safety

SPL LISTING DATA ELEMENTS SECTION

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

PRINCIPAL DISPLAY PANEL - 50 mg/mL Cartridge Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

PRINCIPAL DISPLAY PANEL - 25 mg Vial Carton